

Apidemia IVS

Åbogade 15, 3. sal, 8200 Aarhus N

CVR no. 37 50 33 12

Annual report 2017

Approved at the Company's annual general meeting on 27 February 2018

Chairman:


.....
Mara-Elena Somesan





Contents

Statement by the Executive Board	2
Independent auditors' report on the compilation of financial statements	3
Management's review	4
Financial statements 1 January - 31 December	5
Income statement	5
Balance sheet	6
Statement of changes in equity	8
Notes to the financial statements	9



Statement by the Executive Board

Today, the Executive Board has discussed and approved the annual report of Apidemia IVS for the financial year 1 January - 31 December 2017.

The annual report, which has not been audited, has been prepared in accordance with the provisions of the Danish Financial Statements Act. The Executive Board has the criteria for omission of audit to be met.

In my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company's operations for the financial year 1 January - 31 December 2017.

Further, in my opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

I recommend that the annual report be approved at the annual general meeting.

Aarhus N, 27 February 2018
Executive Board:

A handwritten signature in black ink, appearing to read 'Mara', written over a horizontal dotted line.

Mara-Elena Somesan
CEO

Independent auditor's report on the compilation of financial statements

To the general management of Apidemia IVS

We have compiled the financial statements of Apidemia IVS for the financial year 1 January - 31 December 2017 based on the Company's bookkeeping and other information provided.

The financial statements comprise an income statement, balance sheet, statement of changes in equity and notes, including accounting policies.


We performed this compilation engagement in accordance with ISRS 4410, Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant ethical requirements in the Danish act on approved auditors and audit firms and FSR - Danish Auditors' code of ethics, including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile the financial statements are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile the financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether the financial statements are prepared in accordance with the Danish Financial Statements Act.

Aarhus, 27 February 2018
ERNST & YOUNG
Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28



Tom B. Lassen
State Authorised Public Accountant
MNE no.: mne24820



Management's review

Company details

Name	Apidemia IVS
Address, Postal code, City	Åbogade 15, 3. sal, 8200 Aarhus N
CVR no.	37 50 33 12
Established	1 March 2016
Registered office	Aarhus
Financial year	1 January - 31 December
Executive Board	Mara-Elena Somesan, CEO
Accountant	Ernst & Young Godkendt Revisionspartnerselskab Værkmestergade 25, P.O. Box 330, 8100 Aarhus C, Denmark

Management commentary

Business review

The purpose of the Company is to develop, purchase and sell software and other products and to provide services in that respect. Moreover, the Company engages in related business.

Financial review

The income statement for 2017 shows a loss of DKK 383,675 against a loss of DKK 261,932 last year, and the balance sheet at 31 December 2017 shows a negative equity of DKK 645,606. Management considers the Company's financial performance in the year satisfactory.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.



Financial statements 1 January - 31 December

Income statement

Note	DKK	2017 12 months	2016 10 months
	Gross margin	242,557	-104,785
2	Staff costs	-613,907	-157,129
	Profit/loss before net financials	-371,350	-261,914
	Other financial expenses	-12,325	-18
	Profit/loss before tax	-383,675	-261,932
	Tax for the year	0	0
	Profit/loss for the year	<u>-383,675</u>	<u>-261,932</u>
	Recommended appropriation of profit/loss		
	Retained earnings/accumulated loss	<u>-383,675</u>	<u>-261,932</u>



Financial statements 1 January - 31 December

Balance sheet

Note	DKK	<u>2017</u>	<u>2016</u>
	ASSETS		
	Fixed assets		
	Investments		
	Deposits	27,117	16,828
		<u>27,117</u>	<u>16,828</u>
	Total fixed assets	<u>27,117</u>	<u>16,828</u>
	Non-fixed assets		
	Receivables		
	Trade receivables	9,750	0
	Other receivables	0	3,886
	Prepayments	5,753	0
		<u>15,503</u>	<u>3,886</u>
	Cash	<u>75,948</u>	<u>26,383</u>
	Total non-fixed assets	<u>91,451</u>	<u>30,269</u>
	TOTAL ASSETS	<u><u>118,568</u></u>	<u><u>47,097</u></u>

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	2017	2016
	EQUITY AND LIABILITIES		
	Equity		
	Share capital	1	1
	Retained earnings	-645,607	-261,932
	Total equity	<u>-645,606</u>	<u>-261,931</u>
	Liabilities other than provisions		
	Current liabilities other than provisions		
	Trade payables	16,456	10,000
	Other payables	747,718	299,028
		<u>764,174</u>	<u>309,028</u>
	Total liabilities other than provisions	<u>764,174</u>	<u>309,028</u>
	TOTAL EQUITY AND LIABILITIES	<u>118,568</u>	<u>47,097</u>

1 Accounting policies

3 Contractual obligations and contingencies, etc.

Financial statements 1 January - 31 December

Statement of changes in equity

DKK	<u>Share capital</u>	<u>Retained earnings</u>	<u>Total</u>
Equity at 1 January 2017	1	-261,932	-261,931
Transfer through appropriation of loss	0	-383,675	-383,675
Equity at 31 December 2017	<u>1</u>	<u>-645,607</u>	<u>-645,606</u>

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Apidemia IVS for 2017 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Income statement

Revenue

Income from the rendering of services is recognised as revenue as the services are rendered. Accordingly, revenue corresponds to the market value of the services rendered during the year (percentage-of-completion method).

Gross margin

The items revenue, other operating income and external expenses have been aggregated into one item in the income statement called gross margin in accordance with section 32 of the Danish Financial Statements Act.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to sale, advertising, administration, premises, bad debts, etc.

Staff costs

Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.

Financial expenses

Financial expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Equity

Proposed dividends

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Other payables

Other payables are measured at net realisable value.

Financial statements 1 January - 31 December

Notes to the financial statements

DKK	2017 12 months	2016 10 months
2 Staff costs		
Wages/salaries	599,859	154,560
Other social security costs	4,860	1,136
Other staff costs	9,188	1,433
	613,907	157,129
 Average number of full-time employees	 2	 1

3 Contractual obligations and contingencies, etc.

Other financial obligations

Rent liabilities include a rent obligation totalling DKK 29 thousand in interminable rent agreements with remaining contract terms of 6 months.